Intraperitoneal Chemotherapy for Colorectal Cancer
(ICARuS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, if you are taking an oral medication that cannot be safely stopped for up to ten days, it may be a concern for participation.
Is intraperitoneal chemotherapy for colorectal cancer safe?
Intraperitoneal chemotherapy combined with surgery for colorectal cancer can lead to moderate to high rates of complications and risks, but it is a treatment option for certain patients. Safety data shows that while it can be effective, it comes with significant risks that need to be carefully considered.12345
How is the treatment of cytoreductive surgery with intraperitoneal chemotherapy unique for colorectal cancer?
This treatment is unique because it combines surgery to remove visible tumors with chemotherapy delivered directly into the abdominal cavity, targeting cancer cells more directly than traditional methods. It is particularly used for patients with cancer spread to the lining of the abdomen, offering a more localized approach compared to standard chemotherapy.46789
What data supports the effectiveness of the treatment involving Cytoreductive Surgery, FUDR, Leucovorin, Mitomycin-C, and other components for colorectal cancer?
Who Is on the Research Team?
Garrett Nash, MD, MPH
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with appendiceal or colorectal cancer that has spread to the lining of the abdomen, who are fit enough for surgery and have no other serious medical conditions. They must not be pregnant, should agree to use contraception, and cannot have had prior intraperitoneal chemotherapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Cytoreductive Surgery
Patients undergo optimal cytoreductive surgery to reduce tumor nodules to no greater than 2.5mm
Treatment
Participants receive either Early Post-operative Intraperitoneal Chemotherapy (EPIC) or Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment, including evaluation of chemotherapy and surgical toxicities
Long-term Follow-up
Documentation of tumor recurrence based on surveillance CT/PET CT scans
What Are the Treatments Tested in This Trial?
Interventions
- Cytoreductive Surgery
- FUDR
- Leucovorin
- Mitomycin-C
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
The Cleveland Clinic
Collaborator
Brigham and Women's Hospital
Collaborator
University of Miami
Collaborator
University of Pittsburgh Medical Center
Collaborator
Washington University School of Medicine
Collaborator